| PE | Sector PE | P/B | Div. Yield | ROE |
|---|---|---|---|---|
| 58.63 | 27.88 | 6.48 | 0.02% | 9.66% |
Gufic Biosciences had its CRISIL A-/Stable long-term and A2+ short-term ratings reaffirmed on bank facilities. The total bank loan facilities rated were enhanced to ₹516 crore from ₹425 crore. The company reported consolidated revenue of about ₹944 crore for FY26, with exports contributing roughly 23% of sales. Borrowings stood at ₹280 crore, compared with ₹180 crore a year earlier.
Powered by Tijori
Gufic Biosciences had its CRISIL A-/Stable long-term and A2+ short-term ratings reaffirmed on bank facilities. The total bank loan facilities rated were enhanced to ₹516 crore from ₹425 crore. The company reported consolidated revenue of about ₹944 crore for FY26, with exports contributing roughly 23% of sales. Borrowings stood at ₹280 crore, compared with ₹180 crore a year earlier.
Powered by Tijori
Aug 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES JUNE-QUARTER CONSOL TOTAL PROFIT 223.1 MILLION RUPEES
GUFIC BIOSCIENCES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 2.61 BILLION RUPEES
Further company coverage: GUFI.NS
Aug 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES JUNE-QUARTER CONSOL TOTAL PROFIT 223.1 MILLION RUPEES
GUFIC BIOSCIENCES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 2.61 BILLION RUPEES
Further company coverage: GUFI.NS
Jan 20 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
RECEIVES TAX DEMAND NOTICE FOR 43.3 MILLION RUPEES
Source text: ID:nBSE2cfC1B
Further company coverage: GUFI.NS
Jan 20 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
RECEIVES TAX DEMAND NOTICE FOR 43.3 MILLION RUPEES
Source text: ID:nBSE2cfC1B
Further company coverage: GUFI.NS
Jan 13 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES LTD - GUFIC BIOSCIENCES INVESTS AED 200,000 IN UNIT VEIRA LIFE FZE
Source text: ID:nBSE1j770C
Further company coverage: GUFI.NS
Jan 13 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES LTD - GUFIC BIOSCIENCES INVESTS AED 200,000 IN UNIT VEIRA LIFE FZE
Source text: ID:nBSE1j770C
Further company coverage: GUFI.NS
** Shares of Gufic Biosciences GUFI.NS slip 6.1% to 418.50 rupees
** The pharmaceuticals co's Q2 consol total profit fell 6.2% y/y, revenue down 5% y/y
** Strategic initiatives,including increase in overall market share in Botulinum Toxin products, investments in new biological technology platform and commercialization of immuno-oncology therapy to boost growth over next few years, co says
** Stock up ~32% YTD
(Reporting by Vijay Malkar)
** Shares of Gufic Biosciences GUFI.NS slip 6.1% to 418.50 rupees
** The pharmaceuticals co's Q2 consol total profit fell 6.2% y/y, revenue down 5% y/y
** Strategic initiatives,including increase in overall market share in Botulinum Toxin products, investments in new biological technology platform and commercialization of immuno-oncology therapy to boost growth over next few years, co says
** Stock up ~32% YTD
(Reporting by Vijay Malkar)
Nov 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
SEPT-QUARTER CONSOL TOTAL PROFIT 217.7 MILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 2.04 BILLION RUPEES
Source text: [ID:]
Further company coverage: GUFI.NS
Nov 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
SEPT-QUARTER CONSOL TOTAL PROFIT 217.7 MILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 2.04 BILLION RUPEES
Source text: [ID:]
Further company coverage: GUFI.NS
Aug 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
JUNE-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 208.6 MILLION RUPEES
JUNE-QUARTER REVENUE FROM OPERATIONS 2.03 BILLION RUPEES
RE‐APPOINTMENT OF JAYESH CHOKSI AS CHAIRMAN, MD
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
(Reporting by VijayDattaram Malkar)
Aug 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
JUNE-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 208.6 MILLION RUPEES
JUNE-QUARTER REVENUE FROM OPERATIONS 2.03 BILLION RUPEES
RE‐APPOINTMENT OF JAYESH CHOKSI AS CHAIRMAN, MD
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
(Reporting by VijayDattaram Malkar)
March 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GRANTED PATENT FOR INVENTION ENTITLED LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
March 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GRANTED PATENT FOR INVENTION ENTITLED LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
Feb 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES DEC-QUARTER TOTAL PROFIT 222.6 MILLION RUPEES VERSUS PROFIT 203.4 MILLION RUPEES
GUFIC BIOSCIENCES DEC-QUARTER REVENUE FROM OPERATIONS 2.02 BILLION RUPEES VERSUS 1.77 BILLION RUPEES
Source text for Eikon: ID:nBSE5KSK8Y
Further company coverage: GUFI.NS
Feb 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES DEC-QUARTER TOTAL PROFIT 222.6 MILLION RUPEES VERSUS PROFIT 203.4 MILLION RUPEES
GUFIC BIOSCIENCES DEC-QUARTER REVENUE FROM OPERATIONS 2.02 BILLION RUPEES VERSUS 1.77 BILLION RUPEES
Source text for Eikon: ID:nBSE5KSK8Y
Further company coverage: GUFI.NS
Jan 30 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
CO GRANTED PATENT OF ADDITION FOR FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE
GOT PATENT FOR 20 YEARS
Source text for Eikon: ID:nNSE1hr677
Further company coverage: GUFI.NS
Jan 30 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
CO GRANTED PATENT OF ADDITION FOR FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE
GOT PATENT FOR 20 YEARS
Source text for Eikon: ID:nNSE1hr677
Further company coverage: GUFI.NS
Nov 9 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
INDIA'S GUFIC BIOSCIENCES SEPT-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 232.1 MILLION RUPEES VERSUS 202.1 MILLION RUPEES
GUFIC BIOSCIENCES LTD SEPT-QUARTER REVENUE FROM OPERATIONS 2.15 BILLION RUPEES VERSUS 1.75 BILLION RUPEES
Source text for Eikon: ID:nBSEbNyQpm
Further company coverage: GUFI.NS
Nov 9 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
INDIA'S GUFIC BIOSCIENCES SEPT-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 232.1 MILLION RUPEES VERSUS 202.1 MILLION RUPEES
GUFIC BIOSCIENCES LTD SEPT-QUARTER REVENUE FROM OPERATIONS 2.15 BILLION RUPEES VERSUS 1.75 BILLION RUPEES
Source text for Eikon: ID:nBSEbNyQpm
Further company coverage: GUFI.NS
Sept 27 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
APPROVED INCORPORATION OF UNIT IN DUBAI, UAE
Source text for Eikon: ID:nBSEcgCgsV
Further company coverage: GUFI.NS
Sept 27 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
APPROVED INCORPORATION OF UNIT IN DUBAI, UAE
Source text for Eikon: ID:nBSEcgCgsV
Further company coverage: GUFI.NS
** Shares of Gufic Biosciences GUFI.NS up as much as 4.57% to 310 rupees
** Stock on track for third consecutive session of gains
** Active pharmaceutical ingredients maker said it has been granted 20-year patent for Omadacycline Tosylate, a component used in drugs
** About 201,355 shares change hands as of 10:42 a.m. IST, 0.5x 30-day average
** Stock up ~31% so far this year, as of last close
(Reporting by Manvi Pant in Bengaluru)
((Manvi.Pant@thomsonreuters.com; +918447554364;))
** Shares of Gufic Biosciences GUFI.NS up as much as 4.57% to 310 rupees
** Stock on track for third consecutive session of gains
** Active pharmaceutical ingredients maker said it has been granted 20-year patent for Omadacycline Tosylate, a component used in drugs
** About 201,355 shares change hands as of 10:42 a.m. IST, 0.5x 30-day average
** Stock up ~31% so far this year, as of last close
(Reporting by Manvi Pant in Bengaluru)
((Manvi.Pant@thomsonreuters.com; +918447554364;))
Sept 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GRANTED PATENT FOR INVENTION "FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE AND PROCESS FOR PREPARATION THEREOF"
PATENT GRANTED FOR TERM OF 20 YEARS EFFECTIVE FROM APRIL 19, 2021
Source text for Eikon: ID:nBSE1rQVLF
Further company coverage: GUFI.NS
Sept 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GRANTED PATENT FOR INVENTION "FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE AND PROCESS FOR PREPARATION THEREOF"
PATENT GRANTED FOR TERM OF 20 YEARS EFFECTIVE FROM APRIL 19, 2021
Source text for Eikon: ID:nBSE1rQVLF
Further company coverage: GUFI.NS
** Shares of Gufic Biosciences GUFI.NS rise as much as 7.6% to 319.2 rupees, biggest pct gain since July 27
** Co receives regulatory approval for Parecoxib 40 mg injection from Australia's TGA and Brazil's Anvisa
** Injection to be used for short-term treatment of acute pain and post-operative pain in adult patients
** More than 804,930 shares change hands by 11:20 a.m. IST, 2.0x the 30-day avg of 402,502 shares
** Stock last up 2.6%, bumping YTD gains to ~33%
(Reporting by Ashna Teresa Britto in Bengaluru)
((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))
** Shares of Gufic Biosciences GUFI.NS rise as much as 7.6% to 319.2 rupees, biggest pct gain since July 27
** Co receives regulatory approval for Parecoxib 40 mg injection from Australia's TGA and Brazil's Anvisa
** Injection to be used for short-term treatment of acute pain and post-operative pain in adult patients
** More than 804,930 shares change hands by 11:20 a.m. IST, 2.0x the 30-day avg of 402,502 shares
** Stock last up 2.6%, bumping YTD gains to ~33%
(Reporting by Ashna Teresa Britto in Bengaluru)
((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))
Sept 11 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC RECEIVES TGA AUSTRALIA AND ANVISA BRAZIL APPROVAL FOR PARECOXIB 40MG INJECTION
Source text for Eikon: ID:nBSE2z651g
Further company coverage: GUFI.NS
Sept 11 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC RECEIVES TGA AUSTRALIA AND ANVISA BRAZIL APPROVAL FOR PARECOXIB 40MG INJECTION
Source text for Eikon: ID:nBSE2z651g
Further company coverage: GUFI.NS
Sept 1 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
TO ISSUE SHARES TO MOTILAL OSWAL FINANCIAL SERVICES ON A PREFERENTIAL BASIS
SHARE ISSUE WORTH 999.9 MILLION RUPEES
ISSUE PRICE 300 RUPEES PER SHARE
Further company coverage: GUFI.NS
Sept 1 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
TO ISSUE SHARES TO MOTILAL OSWAL FINANCIAL SERVICES ON A PREFERENTIAL BASIS
SHARE ISSUE WORTH 999.9 MILLION RUPEES
ISSUE PRICE 300 RUPEES PER SHARE
Further company coverage: GUFI.NS
** Shares of active pharmaceutical ingredients (API) maker Gufic Biosciences Ltd GUFI.NS up as much as 6.6% to 247 rupees, their highest since May 20, 2022
** Co on Friday said it received approval from National Medical Products Administration (NMPA), China, for Prilocaine API, an amide-type local anaesthetic
** Co says approval will help in commercialisation of the product in China and help explore Chinese market
** Over 654,000 shares change hands by 10:02 a.m. IST, 4.0x the 30-day moving avg
** As of last close, stock up 2.3% so far this year
(Reporting by Kashish Tandon in Bengaluru)
** Shares of active pharmaceutical ingredients (API) maker Gufic Biosciences Ltd GUFI.NS up as much as 6.6% to 247 rupees, their highest since May 20, 2022
** Co on Friday said it received approval from National Medical Products Administration (NMPA), China, for Prilocaine API, an amide-type local anaesthetic
** Co says approval will help in commercialisation of the product in China and help explore Chinese market
** Over 654,000 shares change hands by 10:02 a.m. IST, 4.0x the 30-day moving avg
** As of last close, stock up 2.3% so far this year
(Reporting by Kashish Tandon in Bengaluru)
June 16 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
RECEIVED APPROVAL FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION, CHINA FOR PRODUCT PRILOCAINE (API)
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
June 16 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
RECEIVED APPROVAL FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION, CHINA FOR PRODUCT PRILOCAINE (API)
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
May 30 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES LTD- CLEARED PHYSICAL AUDIT OF BRAZILIAN HEALTH REGULATORY AGENCY SUCCESSFULLY WITHOUT ANY OBSERVATION
GUFIC BIOSCIENCES LTD- RECEIVED GOOD MANUFACTURING PRACTICES CERTIFICATE FROM ANVISA FOR GUJARAT PLANT
GUFIC BIOSCIENCES LTD- WILL ENABLE CO TO EXPAND BUSINESS IN BRAZIL
Source text for Eikon: ID:nBSE94QRJp
Further company coverage: GUFI.NS
May 30 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES LTD- CLEARED PHYSICAL AUDIT OF BRAZILIAN HEALTH REGULATORY AGENCY SUCCESSFULLY WITHOUT ANY OBSERVATION
GUFIC BIOSCIENCES LTD- RECEIVED GOOD MANUFACTURING PRACTICES CERTIFICATE FROM ANVISA FOR GUJARAT PLANT
GUFIC BIOSCIENCES LTD- WILL ENABLE CO TO EXPAND BUSINESS IN BRAZIL
Source text for Eikon: ID:nBSE94QRJp
Further company coverage: GUFI.NS
May 29 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
INDIA'S GUFIC BIOSCIENCES MARCH-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 181.1 MILLION RUPEES VERSUS PROFIT 202.6 MILLION RUPEES
GUFIC BIOSCIENCES MARCH-QUARTER REVENUE FROM OPERATIONS 1.73 BILLION RUPEES VERSUS 1.62 BILLION RUPEES
Further company coverage: GUFI.NS
May 29 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
INDIA'S GUFIC BIOSCIENCES MARCH-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 181.1 MILLION RUPEES VERSUS PROFIT 202.6 MILLION RUPEES
GUFIC BIOSCIENCES MARCH-QUARTER REVENUE FROM OPERATIONS 1.73 BILLION RUPEES VERSUS 1.62 BILLION RUPEES
Further company coverage: GUFI.NS
| Jun 26(Cr.) | YoY Change | QoQ Change | |
|---|---|---|---|
| Sales | 261 | 16.58% | 3.57% |
| Operating Profit | 46.61 | 39.95% | -1.28% |
| Net profit | 22.31 | 70.72% | 1.9% |
| Type | Jun 26 | Sep 26 | YoY Change | QoQ Change |
|---|---|---|---|---|
| Promoter | 72.50% | 72.50% | -- | -- |
| Pledge | -- | -- | -- | -- |
| FII | 0.47% | 0.44% | 0.11% | -0.03% |
| DII | 3.67% | 3.38% | -0.28% | -0.29% |
| Retail < 2L | 11.41% | 11.72% | 0.1% | 0.31% |
| Others | 11.95% | 11.96% | -- | 0.01% |
| No. of Shareholders | 29,753 | 29,726 | -5.39% | -0.09% |
| Name | M.CAP (Cr.) | PE | ROCE (%) | D/E |
|---|---|---|---|---|
| GUFICBIO | 4,307 | 58.63 | 14.94 | 0.58 |
| ZOTA | 4,264 | -- | -6.49 | 0.04 |
| EVONILE | 4,352 | -- | 8.49 | -- |
| KPL | 3,782 | 46.66 | 27.81 | 0.39 |